Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 180

1.

Prothrombin fragment F1+2 in plasma and urine during total hip arthroplasty.

Borgen PO, Reikeras O.

J Orthop. 2017 Aug 3;14(4):475-479. doi: 10.1016/j.jor.2017.08.001. eCollection 2017 Dec.

PMID:
28831236
2.

Similar Clinical Outcomes with Preoperative and Postoperative Start of Thromboprophylaxis in THA: A Register-based Study.

Borgen PO, Pripp AH, Dybvik E, Leistad L, Dahl OE, Reikerås O.

Clin Orthop Relat Res. 2017 Sep;475(9):2245-2252. doi: 10.1007/s11999-017-5419-1. Epub 2017 Jun 22.

PMID:
28643079
3.

Activation of markers of inflammation, coagulation and fibrinolysis in musculoskeletal trauma.

Reikerås O, Borgen P.

PLoS One. 2014 Nov 3;9(11):e107881. doi: 10.1371/journal.pone.0107881. eCollection 2014.

4.

Acetabular wall augmentation in selected patients with recurrent dislocation after THA.

Sivertsen EA, Borgen PO.

J Arthroplasty. 2014 Nov;29(11):2202-5. doi: 10.1016/j.arth.2014.06.011. Epub 2014 Jun 20.

PMID:
25052045
5.

Changes in serum cytokines in response to musculoskeletal surgical trauma.

Reikeras O, Borgen P, Reseland JE, Lyngstadaas SP.

BMC Res Notes. 2014 Mar 7;7:128. doi: 10.1186/1756-0500-7-128.

6.

Biomarkers of Coagulation and Fibrinolysis during Cemented Total Hip Arthroplasty with Pre- versus Postoperative Start of Thromboprophylaxis.

Borgen PO, Dahl OE, Reikeras O.

Thrombosis. 2013;2013:563217. doi: 10.1155/2013/563217. Epub 2013 Dec 16.

7.

Orbital metastasis as the initial presentation in bilateral lobular invasive carcinoma of the breast.

Saffra N, Rakhamimov A, Wrzolek MA, Solomon WB, Cooper J, Borgen P.

Ophthal Plast Reconstr Surg. 2014 Mar-Apr;30(2):e30-2. doi: 10.1097/IOP.0b013e3182916537. No abstract available.

PMID:
23645354
8.

The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay.

Laronga C, Harness JK, Dixon M, Borgen PI.

Am J Surg. 2012 Jun;203(6):751-8. doi: 10.1016/j.amjsurg.2011.07.024. Epub 2012 Apr 18. Review.

PMID:
22516676
9.

Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis.

Borgen PO, Dahl OE, Reikerås O.

Clin Orthop Relat Res. 2012 Sep;470(9):2591-8. doi: 10.1007/s11999-012-2320-9. Epub 2012 Apr 3.

10.

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators.

N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.

11.

Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA.

Borgen PO, Dahl OE, Reikeras O.

Hip Int. 2010 Jul-Sep;20(3):301-7.

PMID:
20640994
12.

Total Skin Sparing (Nipple Sparing) Mastectomy: What is the Evidence?

Gupta A, Borgen PI.

Surg Oncol Clin N Am. 2010 Jul;19(3):555-66. doi: 10.1016/j.soc.2010.04.006. Review.

PMID:
20620927
13.

Use of text messaging to enhance compliance with the accreditation council for graduate medical education resident duty hour requirements.

Goldstein EB, Savel RH, Chorost MI, Borgen PI, Cunningham J.

J Surg Educ. 2009 Nov-Dec;66(6):379-82. doi: 10.1016/j.jsurg.2009.04.003.

PMID:
20142139
14.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

15.

Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.

Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS 3rd.

J Clin Oncol. 2008 Apr 10;26(11):1803-9. doi: 10.1200/JCO.2007.12.6425. Epub 2008 Mar 10.

PMID:
18332473
16.

Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping.

Olshen AB, Gold B, Lohmueller KE, Struewing JP, Satagopan J, Stefanov SA, Eskin E, Kirchhoff T, Lautenberger JA, Klein RJ, Friedman E, Norton L, Ellis NA, Viale A, Lee CS, Borgen PI, Clark AG, Offit K, Boyd J.

BMC Genet. 2008 Feb 5;9:14. doi: 10.1186/1471-2156-9-14.

17.

Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer?

Chan SW, LaVigne KA, Port ER, Fey JV, Brogi E, Borgen PI, Cody HS 3rd.

Ann Surg. 2008 Jan;247(1):143-9.

PMID:
18156934
18.

MRI screening in a clinic population with a family history of breast cancer.

Yu J, Park A, Morris E, Liberman L, Borgen PI, King TA.

Ann Surg Oncol. 2008 Feb;15(2):452-61. Epub 2007 Nov 17.

PMID:
18026801
19.

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.

Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN.

Breast Cancer Res Treat. 2008 Sep;111(2):377-88. Epub 2007 Oct 20.

PMID:
17952589
20.

The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge.

Morrogh M, Morris EA, Liberman L, Borgen PI, King TA.

Ann Surg Oncol. 2007 Dec;14(12):3369-77. Epub 2007 Sep 26.

PMID:
17896158

Supplemental Content

Loading ...
Support Center